Guggenheim reiterates Buy on EyePoint stock after mixed trial data

Guggenheim has reaffirmed a Buy rating and set a $68.00 price target for EyePoint Inc. (NASDAQ:EYPT) in light of their latest LUGANO Phase III trial for Duravyu. The stock is presently trading at $4.66, with analyst price targets ranging from $20 to $68. According to InvestingPro data, the company may be undervalued, as indicated by their Fair Value analysis.

However, the trial did not achieve its primary goal of demonstrating non-inferiority to aflibercept in reducing best-corrected visual acuity (BCVA). This result was primarily due to the impact of a 4% cohort of patients experiencing vision loss unrelated to wet AMD, which was not present in the control group. An ad hoc analysis, excluding this cohort, found Duravyu to be non-inferior to aflibercept with a nominal p-value of 0.0096.

The trial showed a 42% reduction in treatment burden compared to aflibercept, with patients requiring an average of two fewer injections. Supplement-free rates reached 76% at Week 32 and 54% at Week 56, with 79% of patients receiving zero to one supplements by Week 56. The trial demonstrated a 4-micron difference in contrast sensitivity threshold (CST) versus aflibercept at Week 56 and reported no drug-related serious adverse events, retinal vasculitis, severe intraocular inflammation, or insert migration.

Despite the lack of primary endpoint success, EyePoint Inc. remains a topic of interest, with various analysts providing differing opinions and price targets.